Kornimate/medical-research-clean huggingface dataset:
median effective dose of remifentanil for the prevention of myoclonus induced by etomidate injection

Conditions: Etomidate; Myoclonus

Summary: since its introduction in 1973, etomidate has been widely used in clinical anaesthesia, especially in haemodynamically unstable patients, as a new anaesthetic induction drug with the advantage of low circulatory and respiratory depression. when administered via intravenous injection, etomidate can cause adverse effects such as injection pain and myoclonus. the incidence of myoclonus is still reported to be as high as 50-80%. myoclonus caused by etomidate may cause discomfort during induction of anaesthesia and reduce perioperative satisfaction, and may lead to syringe dislodgement, extravasation of the injected drug, swelling at the injection site, delayed induction of anaesthesia and, in severe cases, cardiovascular adverse events. therefore, the myoclonus and limb retraction reactions caused by etomidate are a key concern for clinical anaesthesiologists and need to be addressed at a time when comfort anaesthesia is being promoted. the aim of this study was to reduce myoclonus produced by etomidate injection during induction of general anaesthesia in surgical patients and to investigate the half effective dose of remifentanil to reduce etomidate myoclonus.


Eligibility criteria:
inclusion criteria: 1. ages ranged from 18 to 80. 2. asa # or # level. exclusion criteria: * allergy or contraindication to remifentanil or rocuronium; required for central venipuncture catheterization; * abnormal liver or kidney function; * heavy drinking and long-term use of sedatives, analgesics or anti-anxiety drugs; * hearing and language impairment; * peripheral vascular disease; * severe cardiovascular disease or neurological disorders; * failure of one-time peripheral venipuncture; * infection of hand or wrist skin.
fluorescent imaging of nerves with illuminare-1 during surgery

Conditions: Prostate Adenocarcinoma

Summary: this study will test the safety of using illuminare-1 during standard surgery for prostate cancer. the study researchers will test increasing doses of illuminare-1 to find the dose that makes the nerve structures fluoresce (light up) but causes few or mild side effects. when the researchers find this dose, it will be tested in new groups of study participants to see whether surgery performed using illuminare-1 guidance is better than surgery performed without intraoperative guidance. the researchers will also do tests to study the way the body absorbs, distributes, and gets rid of illuminare-1. this study is the first to test illuminare-1 in people. illuminare-1 has received fast track designation from the us fda.


Eligibility criteria:
inclusion criteria: * 18 years or older and capable of signing their own consent form * scheduled for minimally invasive radical prostatectomy with pelvic lymph node dissection exclusion criteria: * prior pelvic surgery or pelvic radiation therapy * known central nervous or peripheral nervous system disease or insult (including neurodegenerative diseases), current use of neurotoxic medications, or use of cytotoxic chemotherapy with known neurotoxicity within 1 month * exposure to investigational agents in the immediate 30 days before or 15 days after study drug administration * patients with significant renal dysfunction (\<60 ml/min as assessed by the cockcroft gault calculation for creatinine clearance) * clinically significant hepatic/liver impairment (liver function tests more than 2x institutional normal upper limit) * exposure to phototoxic drugs such as st. john's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines, should be avoided. if safe to discontinue use for a limited time, patients may participate on this trial but will discontinue the use of the interfering drug for 5 half-lives before illuminare-1 injection to permit full washout, as well as for 48 hours after administration of illuminare-1.

Keywords: fluorescent imaging illuminare-1 myelin-binding fluorophore 21-099
intravitreal lfg316 in patients with advanced age-related macular degeneration

Conditions: Advanced Age-related Macular Degeneration

Summary: this study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal lfg316 in patients with advanced age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * male or female amd patients 55 to 90 years old, inclusive. in either eye, diagnosis of geographic atrophy or choroidal neovascularization due to amd * etdrs best corrected visual acuity of 60 letters or worse in the study eye. exclusion criteria: * retinal disease other than amd in study eye which, in the investigator's opinion, may pose a safety risk or interfere with the study. * choroidal neovascularization due to a cause other than amd. * in the study eye, media opacity that interferes with fundus imaging or is likely to require surgery during the study period. * any of the following treatments to the study eye within 14 days prior to dosing: ranibizumab (lucentis), bevacizumab (avastin), pegaptanib (macugen), or other vegf inhibitor; or likely requirement for one of the above treatments within 14 days of lfg316 administration. * any of the following within 30 days prior to dosing: photodynamic therapy treatment in the study eye; extrafoveal or juxtafoveal thermal laser photocoagulation in the study eye; systemic or topical (ophthalmic) steroid use in the study eye; bacterial keratitis in the study eye; or intraocular surgery (including cataract surgery) in the fellow eye. * any of the following within 90 days prior to dosing: intraocular surgery (including cataract surgery) in the study eye; or intravitreal or periocular corticosteroid injection in the study eye. * participation in another interventional clinical study, or use of any experimental treatment for amd or any other investigational new drug within 12 weeks prior to the start of study treatment. clinical trials solely involving over-the-counter vitamins, supplements, or diets will not exclude the patients from study participation. * any medical condition likely to interfere with the patient's participation in the study, or likely to cause serious adverse events during the study. other protocol-defined inclusion/exclusion criteria may apply

Keywords: amd, armd, age-related macular degeneration, eye disease, wet amd, neovascular amd, choroidal neovascular membrane, choroidal neovascularization, drusen, geographic atrophy, complement, c5, antibody
effect of intra-procedure music on anxiety

Conditions: Anxiety

Summary: the purpose of this study is to examine the effects of intra-procedure music intervention on procedural anxiety, physiological stress and sedation requirements in patients undergoing moderate sedation procedures. study participants will be randomly assigned into two groups: 1. control - standard care without music intervention. 2. intervention - standard of care plus music intervention. the state-trait anxiety inventory questionnaire will be provided pre, intra and post procedure to all subjects in addition to an exit survey.


Eligibility criteria:
inclusion criteria: * adult (\>18 years old) patients * scheduled for moderate sedation procedures in the interventional radiology department at tisch hospital, nyu langone health in new york, new york * able to read and write in english at a sixth grade level (stai is written at sixth grade comprehension level) exclusion criteria: * not a moderate sedation candidate (hemodynamically unfit, not optimized for procedure, pregnant)
dementia risk registry for young and middle-aged csvd patients in the next 10 years

Conditions: Cerebral Small Vessel Diseases; Dementia, Mixed; Health Behavior; Health Behavior, Risky

Summary: age-related cerebral small-vessel disease (csvd) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population. however, the correlation between the burden of csvd and the progression of cognitive impairment in young and middle-aged individuals remains uncertain. dream-10 is an observational, prospective study that enrolled individuals aged 30-60 years, who were free from known dementia but exhibited imaging markers related to csvd. through prospective registration and follow-up, this study will collect data on patients with csvd, including clinical information, neuropsychological assessments, multimodal magnetic resonance images (mri) and retinopathy characterized by optical coherence tomography angiography (octa). csvd related features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, brain atrophy, cortical superficial siderosis. utilizing this data, the researchers aim to investigate the potential dementia risk among young and middle-aged individuals with csvd over the forthcoming decade, along with identifying its predictive factors.


Eligibility criteria:
inclusion criteria: 1. patients with any of the csvd-related mri imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis. 2. patients aged from 30 to 60 years. 3. sign informed consent. exclusion criteria: 1. unable to cooperate with inspectors. 2. known dementia. 3. other cognitive diseases (such as alzheimer's disease, parkinson's disease, or thyroid disease). 4. serious systemic illness, such as heart, liver, kidney disease or major mental illness. 5. contraindications for imaging examination. exit criteria: 1. not meet the inclusion criteria. 2. for any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator. 3. any adverse or serious adverse events during the study period judged by investigator.

Keywords: cerebral small vessel diseases dementia cardiovascular health
covid-19 in osteoarthritis patients

Conditions: Osteoarthritis

Summary: while the coronavirus pandemic has spread rapidly around the world, it has generated a considerable degree of fear, concern and anxiety among the population in general and among certain groups in particular, such as older persons. initial findings from studies in china indicated the presence of moderate to severe psychological impact in a significant proportion of individuals and an increased prevalence of post-traumatic stress symptoms. it should also be noted that other types of symptoms, such as anxiety and depression, appeared to persist over time and to a greater extent. osteoarthritis can develop in any joint, but most often affects the knees, hands and hips. people with osteoarthritis are often older and sometimes more frail than the general population. the main recommendations for non-drug treatment of osteoarthritis include education, physical activity and structured exercise programmes with or without weight reduction. due to the confinement associated with covid-19, many patients have had to stop exercise/physical activity and postpone prosthetic surgery. apart from the context of delay in surgery, there is little data available on the impact of the pandemic on people with arthritis. several questions are therefore still pending concerning the impact of the pandemic on these patients. the investigators hypothesise that the following therapeutic modalities have been disrupted during this period: access to care, scheduling of prosthetic surgery, consumption of painkillers or nsaids, recourse to physical activities, recourse to physiotherapy sessions, weight changes, level of pain.... our objective is to evaluate the physical, social, psychological and behavioural consequences of the covid-19 pandemic in a cohort of osteoarthritis patients.


Eligibility criteria:
inclusion criteria: - oa patients exclusion criteria: * active or passive opposition of the patient and / or its legal representatives to participate in the study.

Keywords: lower limbs anxiety stress covid19
diagals: relation between tar dna binding protein(tdp)-43 et nrf-2 in als: a track to improve diagnosis and prognosis of the disease

Conditions: Amyotrophic Lateral Sclerosis

Summary: in response to oxidative stress, cells activate the nrf-2 pathway, which induces translation of its target genes and corresponding proteins involved in the antioxidant response. this explains the interest in the nrf-2 pathway in the pathophysiology of amyotrophic lateral sclerosis (als), supported by the results of several studies and the modulatory effect of tdp-43 on the nrf-2 pathway. since both tdp-43 and nrf-2 proteins are present in the peripheral blood mononuclear cells (pbmc) of als patients and may be correlated with disease progression, the investigators wish to explore their relationship and their application in the clinic as potential blood biomarkers for als.


Eligibility criteria:
patients group : inclusion criteria: * men and women ≥ 18 years old * person affiliated to a french social security scheme or equivalent * als diagnosed according to el escorial criteria * diagnosis of als \< 6 months * onset of symptoms \< 2 years * signed informed consent non-inclusion criteria : * pregnant or breast-feeding * treatment with oral or injectable anticoagulants, antiplatelet agents (except aspirin at the maximum authorized dosage of 160 mg per day) * unbalanced diabetes * long-term corticosteroid therapy * persons deprived of their liberty by judicial or administrative decision; persons under legal protection: guardianship or curators * genetic mutations associated with als control group : inclusion criteria: * male or female volunteer aged 18 or over * person affiliated to a french social security scheme or equivalent * signed informed consent non-inclusion criteria : * pregnant or breast-feeding women * treatment with oral or injectable anticoagulants, antiplatelet agents (except aspirin at the maximum authorized dosage of 160 mg per day) * unbalanced diabetes * long-term corticosteroid therapy * neurological diseases * patient under legal protection (safeguard of justice, curators and guardianship), or in a situation of deprivation of liberty * genetic mutations associated with als
ologen (oculusgen)-glaucoma and pterygium historical control study in china beijing hospital

Conditions: Glaucoma; Pterygium

Summary: the purpose of this study is to determine whether the oculusgen collagen matrix is effective and safe to implant as an aid of glaucoma and pterygium surgeries.

ologen (oculusgen) collagen matrix is a porous, scaffold matrix. it is to be implanted on the top of the scleral flap and beneath the conjunctiva and tenon's capsule at the end of trabeculectomy. the pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. the space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. immediately after implantation, the collagen matrix is absorbed with the aqueous humor that brings a certain pressure press on the top of the scleral flap which makes the dynamic balance for the aqueous system keep the iop in the right side. the collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (iop).

Eligibility criteria:
inclusion criteria: * aged 18 years or over * patient able to cooperate with study procedures and able to perform tests reliably * patient willing to sign informed consent * patient able and willing to complete postoperative follow-up requirements * glaucoma: one/both eye(s) is/are affected by glaucoma * pterygium: patient with pterygium exclusion criteria: * known allergic reactions to collagen

Keywords: glaucoma pterygium collagen matrix oculusgen trabeculectomy anti scarring pterygium recurrence tissue engineering aeon astron
high frequency deep sclerotomy (hfds) ab interno a combination surgical intervention using cataract surgery to lower iop

Conditions: Cataract; Glaucoma; POAG

Summary: objective: to compare intraocular pressure lowering effect of combined sclerotomy ab interno with phacoemulsification and phacoemulsification alone, in primary or secondary open angle glaucoma patients. study design: prospective, randomized, case- control interventional surgical trial


Eligibility criteria:
inclusion criteria: patients suffering from primary open-angle glaucoma (poag) inadequately controlled with maximum tolerated medical therapy and who will be treated with cataract surgery. exclusion criteria: * one eyed patients * unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits * the presence of extreme narrow angle with complete or partial closure in either eye, except for occludable angles treated with a patent iridectomy * any abnormality preventing reliable applanation tonometry, any opacity or patient uncooperativeness that would restrict adequate examination of the ocular fundus or anterior chamber of either eye * the risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's opinion * any clinically significant, serious, or severe medical or psychiatric condition; any condition that, in the investigator's opinion, would interfere with optimal participation in the study or present a special risk to the patient * participation in any other investigational study within 30 days prior to baseline visit

Keywords: hfds ab interno migs surgery
phase ii study of gefitinib plus nimotuzumab versus gefitinib in non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer (NSCLC)

Summary: combining nimotuzumab to gefitinib may not only potentiate cellular cytotoxicity, but may also assist in overcoming inherent or acquired resistance to gefitinib alone.

reversible egfr tyrosine kinase inhibitors (tki), such as gefitinib, were shown to be effective in patients with non-small cell lung cancer (nsclc). however, patients almost invariably develop resistance to tkis and have disease progression. nimotuzumab is a humanized monoclonal antibody targeting the egfr. combining nimotuzumab to gefitinib may not only potentiate cellular cytotoxicity, but may also assist in overcoming inherent or acquired resistance to gefitinib alone.

Eligibility criteria:
inclusion criteria: * provision of written informed consent prior to any study specific procedures * unresectable non-small cell lung cancer * ecog performance status of 0 to 2 * male or female; ≥ 20 years of age * subjects whose disease has progressed after platinum-based chemotherapy * subjects with measurable lesion exclusion criteria: * inadequate organ functions * disease progression after 2 or more previous chemotherapy regimens * prior therapy with egfr-tyrosine kinase inhibitor or anti-egfr monoclonal ab * any clinically significant gastrointestinal abnormalities * past medical history of interstitial lung disease * pregnant or lactating female
screening for undiagnosed type 2 diabetes in new classes of subjects at high risk

Conditions: Diabetes Mellitus, Type 2

Summary: the study aims to evaluate ifg, igt or unknown type 2 diabetes mellitus in new classes at high risk to develop alterations of glucose metabolism and definition of new pathogenic mechanisms of insulin resistance and atherosclerosis. the following classes of subjects at high risk will be considered:first degree relatives of patients with type 2 diabetes mellitus, patients with cardiovascular disease and stroke, patients with heart valve disease. age will be \> 30 years, both gender.

the primary outcome of the study is evaluation of glucose tolerance, insulin sensitivity and insulin secretion before and 2 hours post-glucose load secondary outcomes are evaluation of endothelial function, of natriuretic peptides and free fatty acids, and inflammation before and 2 hours post-glucose load. new candidate genes will be also evaluated.

Eligibility criteria:
inclusion criteria: * fasting glucose levels \<126 mg/dl * age \>30 years * both male and female exclusion criteria: * type 1 diabetes * known type 2 diabetes mellitus * pregnancy * impaired kidney and liver function * previous history of malignancies

Keywords: cardiovascular disease glucose intolerance type 2 diabetes endothelial dysfunction inflammation age> 30 years, male and female fasting glucose below 126 mg/dl
vietnam cryptococcal retention in care study (crics) federal financial report

Conditions: Cryptococcal Meningitis

Summary: crics financial report for the first budget year of the study

vietnam cryptococcal retention in care study (crics) federal financial report for the first budget year of the study

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years * confirmed hiv infection using national testing algorithm * cd4 ≤100 cells/μl * able to provide written informed consent exclusion criteria: * history of prior cm * receipt of systemic antifungal medication for more than 4 consecutive weeks within the past 6 months * currently taking art or history of art for more than 4 weeks within the past year * known to be currently pregnant or planning to become pregnant during the study period

Keywords: cryptococcal antigenemia cryptococcal meningitis hiv/aids
aorfix intelliflex first in human study

Conditions: Aortic Aneurysm, Abdominal

Summary: the first in human (fih) study is a long-term, single center, non-randomized study established by lombard medical, inc. to collect "on-label" data in the clinical setting on patients undergoing endovascular repair with intelliflex™, the latest generation of the aorfix™ aaa flexible stent graft delivery system, for treatment of abdominal aortic and aorto-iliac aneurysms in anatomy where the aorta in the aneurysm neck is bent through an angle between 0° and 90°.


Eligibility criteria:
inclusion criteria: 1. diagnosed abdominal aortic aneurysm with indication for endovascular repair. 2. intention to electively implant the aorfix™ stent graft system with intelliflex™ delivery device. exclusion criteria: 1. do not comply with the indications for aorfix™ in the ifu. 2. unwillingness or inability to comply with the recommended follow-up assessments according to the standards of care of the investigative site. 3. unwillingness or inability to provide informed consent to both the study and the evar procedure. 4. patients in whom aorfix™ is being placed as a secondary procedure to a previous surgical or endovascular treatment of an aaa other than with another aorfix™ graft.

Keywords: endovascular evar neck angulation